Psychedelics

The market researcher anticipates a 14.5% CAGR during the 2021-2026 forecast period

The new member organization consists of over 78,000 psychiatrists

New amendment to the Mental Health Services Protection Regulation has been initiated to effectively safeguard patients

Although the effects were weaker and more prone to bias, microdoses also seemed to be efficient in pain management

The company plans to use mushroom tea to treat patients pending regulatory approvals

Company intends to provide ketamine therapy at a much lower price than a visit to the clinic would cost

Company will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics Z-Pod technology

These relatively new stores remind people about the final days of the cannabis prohibition era in Canada

Shipment marks company's first successful export to Europe and second to date

Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward

Non-profit says Canada needs to make room for healthcare innovation with respect to psychedelic therapies

Neurology Centre of Toronto in Forest Hill expands its therapy catalogue

New study will compare the effects of MDA and MDMA in humans for the first time

Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic

Film screening was followed by audience Q&A session hosted by director

New clinical research will assess efficacy of IV formulation for the treatment of strokes

Company believes it has completed the largest mushroom harvest Canada has ever seen

The study assessed differences between psilocybin and escitalopram on common signs in MDD

Free virtual conference will discuss unique requisites of psychedelic clinical development

Patient participated in ketamine and psilocybin sessions through the Special Access Program from Health Canada

Clinical trial will be conducted as part of the ATMA Journey Centre's psychedelic-assisted therapist training program

Influencing policies, cataloguing proof of efficacy and assisting veterans integration processes will be ideal outcomes from partnership

Discovery of new drugs follows company decision to extend research outside of tryptamine class, i.e. psilocybin and DMT

Mexican clinical practice releases 'most complete and up-to-date known summary' regarding plant-derived psychoactive substance

The psilocybin producer will be working with the Knowde Group, Inc., BC Green Pharmaceuticals Inc. and Promises Innovative Recovery (PIR)

Application follows successful pre-clinical animal studies at the University of Arkansas

Novel proprietary psychedelic molecule continues to demonstrate potential for treating cocaine dependency

Biopharmaceutical company administers optimized form of LSD in Phase 2b dose-optimization trial

New York law firm forms multidisciplinary association intended to serve the psychedelic industry

New license is the final required step before administering doses to study participants

COO Kevin Nicholson was appointed as the new CEO

Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies

Multi-disciplinary controlled substance company set to commence operations at Calgary facility

Upcoming event said to feature powerful female speakers from broad cross-section of practices and expertise

The company and Hartle will host a virtual press conference scheduled for Wednesday at 1 pm

Biotechnology company will supply InterVivo and clients with clinical-grade MDMA for scientific analyses

New clients offer detailed enthusiastic feedback thus far

Award-winning documentary sequel to be followed by Q&A with renowned psychedelic community figures

'Largest' psilocybin access and data campaign intended to forward mission of promoting fungi-assisted psychotherapy

Cohen Foundation proudly supports organization dedicated to aiding underserved communities